ORTEXORTEX News
Tracking 9984? Get live short interest, options flow, and signals on ORTEX.Sign up free →
99
Earnings Preview9984

SoftBank's Vision Fund Bet Faces Its Next Test

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 4 Aug 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

SoftBank Group Corp. heads into its August 6 earnings report with the borrow market fully relaxed and short sellers largely absent — leaving the outcome entirely to fundamentals.

Short pressure on SoftBank is negligible by almost any measure. Short interest runs at roughly 0.6% of free float, well below the threshold where bearish positioning becomes a meaningful narrative. Borrow availability is extraordinarily loose at over 3,270% — meaning there are more than thirty shares available to lend for every one currently borrowed. That figure has eased slightly over the past week but remains near the highest levels of the past year. The cost to borrow has risen sharply — up 59% over the past week to 1.33% — but from such a low base that it signals little more than a routine drift rather than any squeeze dynamic. With the ORTEX short score sitting at a stable 27.3, shorts are not building ahead of the print.

The debate around SoftBank is structural rather than tactical. Bulls point to the Vision Fund portfolio's leverage to private and public AI investment, a momentum profile ranked at the 74th percentile versus peers, and a consensus price target of roughly ¥7,651 against the current price of ¥5,393 — a gap of more than 40% that implies the Street sees material upside even after a difficult month. That monthly drop of nearly 13% has widened the discount without, so far, triggering a wave of analyst target cuts — no recent changes have landed in the past two weeks. Bears focus on what the ORTEX stock note flags as genuine weak spots: an f-score of just 2, distorted valuation metrics driven by the conglomerate structure, and a price-to-book of 1.56 that has compressed 27 basis points over the past thirty days. The EV/EBITDA multiple of 26.6x remains elevated relative to the business's underlying cash generation.

Ownership concentration adds another layer of interest. Masayoshi Son controls 34% of shares, making every strategic signal from management disproportionately significant. Among institutional holders, Capital Research added over 6.3 million shares as of June 30, while Vanguard trimmed modestly. The absence of any major institutional exodus suggests patient holders rather than nervous ones — consistent with the broadly relaxed borrow market.

Earnings history shows mixed short-term reactions. The June 2026 release produced a 9.3% single-day gain that then reversed into a 7.9% five-day loss. The May 2026 print went the other way: a 3.6% drop on the day extended to a 15.8% drawdown over the following week. The print on Thursday will test whether the Vision Fund's AI positioning can justify the gap between where the stock trades today and where analysts think it belongs.

Stocks in this article

See the live data behind this article on ORTEX.

Open 9984 on ORTEX →

How this article was generated

Generated
4 Aug 2026, 04:18
Data as of
4 Aug 2026, 04:01
Prompt version
v1.0
Data sources
Cost to borrowUtilizationEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.